

and said recombinant polynucleotide comprises a promoter sequence operably linked to a polynucleotide encoding the polypeptide of SEQ ID NO:5 claim 1, and

b) recovering the polypeptide so expressed.

9. (Withdrawn) An isolated antibody which specifically binds to a polypeptide of claim

1.

10. (Currently Amended) An isolated polynucleotide selected from the group consisting of:

- a) a polynucleotide comprising a polynucleotide sequence of SEQ ID NO:10,
- b) a polynucleotide comprising a naturally occurring polynucleotide sequence having at least 90% sequence identity to a polynucleotide sequence of SEQ ID NO:10,
- c) a polynucleotide completely complementary to a polynucleotide of a),
- d) a polynucleotide completely complementary to a polynucleotide of b), and
- e) an RNA equivalent of a)-d).

11. (Original) An isolated polynucleotide comprising at least 60 contiguous nucleotides of a polynucleotide of claim 10.

12. (Withdrawn) A method for detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide of claim 10, the method comprising:

- a) hybridizing the sample with a probe comprising at least 16 contiguous nucleotides comprising a sequence complementary to said target polynucleotide in the sample, and which probe specifically hybridizes to said target polynucleotide, under conditions whereby a hybridization complex is formed between said probe and said target polynucleotide, and
- b) detecting the presence or absence of said hybridization complex, and, optionally, if present, the amount thereof.

13. (Withdrawn) A method of claim 12, wherein the probe comprises at least 30 contiguous nucleotides.

**IN THE CLAIMS**

Please amend claims 8 and 10 as follows.

This listing of the claims replaces all prior versions of the claims in the application.

1. (Withdrawn) An isolated polypeptide selected from the group consisting of:
  - a) a polypeptide comprising an amino acid sequence of SEQ ID NO:5,
  - b) a polypeptide comprising a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence of SEQ ID NO:5,
  - c) and an immunogenic fragment of a polypeptide having an amino acid sequence of SEQ ID NO:5, said fragment consisting of at least 40 contiguous amino acid residues of SEQ ID NO:5.
2. (Withdrawn) An isolated polypeptide of claim 1 comprising SEQ ID NO:5.
3. (Original) An isolated polynucleotide encoding a polypeptide of claim 1.
4. (Previously Amended) An isolated polynucleotide of claim 3 comprising SEQ ID NO:10.
5. (Original) A recombinant polynucleotide comprising a promoter sequence operably linked to a polynucleotide of claim 3.
6. (Original) A cell transformed with a recombinant polynucleotide of claim 5.
7. (Canceled)
8. (Currently Amended) A method for producing a polypeptide of SEQ ID NO:5 claim 1, the method comprising:
  - a) culturing ~~a cell~~ the cell of claim 6 under conditions suitable for expression of the polypeptide, wherein said cell is transformed with a recombinant polynucleotide,

14. (Withdrawn) A method of claim 12, wherein the probe comprises at least 60 contiguous nucleotides.

15. (Withdrawn) A pharmaceutical composition comprising an effective amount of a polypeptide of claim 1 and a pharmaceutically acceptable excipient.

16-22. (Canceled)

23. (Withdrawn) A method for screening a compound for effectiveness in altering expression of a target polynucleotide, wherein said target polynucleotide comprises a sequence of claim 4, the method comprising:

- a) exposing a sample comprising the target polynucleotide to a compound, and
- b) detecting altered expression of the target polynucleotide.

24. (Withdrawn) A microarray wherein at least one element of the microarray is a polynucleotide of claim 11.

25. (Withdrawn) A method of generating an expression profile of a sample which contains polynucleotides, the method comprising:

- a) labeling the polynucleotides of the sample,
- b) contacting the elements of the microarray of claim 24 with the labeled polynucleotides of the sample under conditions suitable for the formation of a hybridization complex, and
- c) quantifying the expression of the polynucleotides in the sample.

26. (Withdrawn) A method of detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide of claim 10, the method comprising:

- a) amplifying said target polynucleotide or fragment thereof using polymerase chain reaction amplification, and
- b) detecting the presence or absence of said amplified target polynucleotide or fragment thereof, and, optionally, if present, the amount thereof.

27. (Withdrawn) A method of assessing toxicity of a test compound, the method comprising:

- a) treating a biological sample containing nucleic acids with the test compound,
- b) hybridizing the nucleic acids of the treated biological sample with a probe comprising at least 20 contiguous nucleotides of a polynucleotide of claim 10 under conditions whereby a specific hybridization complex is formed between said probe and a target polynucleotide in the biological sample, said target polynucleotide comprising a polynucleotide sequence of a polynucleotide of claim 10 or fragment thereof,
- c) quantifying the amount of hybridization complex, and
- d) comparing the amount of hybridization complex in the treated biological sample with the amount of hybridization complex in an untreated biological sample, wherein a difference in the amount of hybridization complex in the treated biological sample is indicative of toxicity of the test compound.